Payment overview · 2025
General Payments
$13.85
1 reported records · 1 companies
Healthcare provider profile · identity verified
Greta Dunn, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CHARLOTTE COURTHOUSE, VA · NPI 1184996910
Verified facts
What the public records show
CMS Open Payments records show Greta Dunn, NP received $13.85 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.85 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $13.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 20 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 185 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 146 | 51 |
| Lisinopril | Lisinopril | 143 | 50 |
| Omeprazole | Omeprazole | 101 | 35 |
| Gabapentin | Gabapentin | 94 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 93 | 29 |
| Losartan Potassium | Losartan Potassium | 89 | 31 |
| Metformin Hcl | Metformin Hcl | 80 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 72 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 14 |
| Famotidine | Famotidine | 64 | 27 |
| Mirtazapine | Mirtazapine | 63 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Furosemide | Furosemide | 54 | 22 |
| Ozempic | Semaglutide | 52 | 11 |
| Prednisone | Prednisone | 52 | 36 |
| Montelukast Sodium | Montelukast Sodium | 47 | 11 |
| Jardiance | Empagliflozin | 42 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 42 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 17 |
| Trazodone Hcl | Trazodone Hcl | 40 | 13 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 13 |
| Meloxicam | Meloxicam | 35 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 34 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 31 | 15 |
| Simvastatin | Simvastatin | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Ibuprofen | Ibuprofen | 26 | 14 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Torsemide | Torsemide | 25 | 11 |
| Tramadol Hcl | Tramadol Hcl | 25 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Mupirocin | Mupirocin | 22 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Carvedilol | Carvedilol | 21 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Nystatin | Nystatin | 18 | 11 |
| Diazepam | Diazepam | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Baclofen | Baclofen | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13.85 · 1 records | GlaxoSmithKline, LLC. | AREXVY, BEXSERO, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error